Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

KemPharm's Opioid Apadaz Will Likely Miss Out On Abuse Deterrence Claim

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA advisory committee unimpressed with 'baby step' to prevent snorting abuse, but the immediate release hydrocodone combo product seems headed to the market even without a differentiated label.

Advertisement

Related Content

Keeping Track: Biosimilar Submissions Galore (And An Approval), Bayer Gets An Oncology Approval, KemPharm Resubmits Apadaz NDA
KemPharm Seeks FDA Dispute Resolution Over Apadaz's Abuse Deterrence
Opioid Approval Standards Not Up For Debate, FDA Tells Advisory Cmte.
Opioid REMS Prescriber Education Should Be Mandatory, FDA Panel Says

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS079477

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel